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Background: Despite improvements in management, infective endocarditis remains 
associated with high mortality and morbidity. We describe temporal changes in the incidence, 
microbiology and outcomes of infective endocarditis and the impact of changes in national 
antibiotic prophylaxis guidelines on incident infective endocarditis. 
Methods: Using a Scotland-wide, individual-level linkage approach, all patients hospitalized 
with infective endocarditis from 1990 until 2014 were identified and linked to national 
microbiology, prescribing and morbidity and mortality datasets. Linked data were used to 
evaluate trends in the crude and age- and sex-adjusted incidence and outcomes of infective 
endocarditis hospitalizations. From 2008, microbiology data and associated outcomes adjusted 
for patient demographics and comorbidity were also analyzed. An interrupted time series 
analysis was performed to evaluate incidence before and after changes to national antibiotic 
prophylaxis guidelines. 
Results: There were 7,638 hospitalizations (65±17 years, 51% females) with infective 
endocarditis. The estimated crude hospitalization rate increased from 5.3/100,000 (95% 
confidence interval [CI] 4.8-5.9) to 8.6/100,000 (95% CI 8.1-9.1) between 1990 and 1995 but 
remained stable thereafter. There was no change in crude incidence following the 2008 change 
in antibiotic prophylaxis guidelines (relative risk of change 1.06, 95% CI 0.94-1.20).  The 
incidence rate in patients >80 years doubled from 1990 to 2014 (17.7/100,000 [95% CI 13.4-
23.3] to 37.9/100,000 [95% CI 31.5-45.5]). The predicted 1 year age- and comorbidity-adjusted 
case fatality rate for a 65 year-old patient decreased in women (27.3% [95% CI 24.6-30.2] to 
23.7% [95% CI 21.1 to 26.6]) and men (30.7% [95% CI 27.7-33.8] to 26.8% [95% CI 24.0-
29.7]) from 1990 to 2014. Blood culture data were available from 2008 (n=2,267/7,638, 30%), 
with positive blood cultures recorded in 42% (950/2,267). Staphylococcus (403/950, 42.4%) 
and streptococcus (337/950, 35.5%) species were most common. Staphylococcus aureus and 
enterococcus had the highest 1 year mortality (adjusted odds ratio 4.34 [95% CI 3.12-6.05] and 
3.41 [95% CI 2.04-5.70], respectively). 
Conclusions: Despite changes in antibiotic prophylaxis guidelines, the crude incidence of 
infective endocarditis has remained stable. However, the incidence rate has doubled in the 
elderly. Positive blood cultures were observed in less than half of patients, with Staphylococcus 




What is new? 
• Several studies have recently evaluated the changing epidemiology of infective 
endocarditis before and after guideline recommendations. These studies have 
predominantly studied the incidence, rather than the outcomes or microbiology, of 
infective endocarditis. 
• Using a national, individual patient-level linkage approach, we describe the changing 
age- and sex-stratified incidence and outcomes of infective endocarditis in Scotland 
between 1990 and 2014. 
• We further describe temporal changes in patient characteristics and microbiology based 
on positive blood cultures associated with infective endocarditis. 
What are the clinical implications?  
• The crude incidence rate of infective endocarditis hospitalizations increased from 
1990 to 1995 but has remained relatively static thereafter with both short- and long-
term adjusted case fatality rates showing a steady decrease over the last 25 years.  
• The majority of patients with endocarditis in our cohort did not have positive blood 
cultures and in those with positive microbiology, staphylococcus and enterococcus 
conferred the highest risk for all-cause mortality.  
• Changes in guidelines regarding antibiotic prophylaxis in the United Kingdom have 






Despite recent improvements in management, infective endocarditis remains associated with 
high morbidity and mortality.1, 2 Over the last few decades, several factors have impacted on 
both the incidence and outcomes of infective endocarditis. The population at-risk of infective 
endocarditis has increased due to changes in population demographics, a rise in the use of 
implantable cardiac devices, an increase in the number of patients undergoing hemodialysis for 
end-stage renal failure, and a greater number of patients with congenital heart disease surviving 
to adulthood.3 Changes in national guidelines regarding the use of antibiotic prophylaxis for 
prevention of infective endocarditis4,5 have also been implicated in the apparent increase in the 
incidence of infective endocarditis.  
 
Several studies have recently evaluated the changing epidemiology of infective endocarditis, 
predominantly incidence,6 before and after guideline recommendations.4, 7-10 Fewer studies 
have evaluated microbiological causes and associated outcomes of endocarditis.11, 12  Using a 
national linkage approach, we describe the changing age- and sex-stratified incidence and 
outcomes of infective endocarditis in Scotland over the last 25 years and the impact of changes 
in national guidelines on antibiotic prophylaxis. With the availability of a national 
microbiology surveillance registry from 2008 onwards, we additionally describe the 
microbiology of infective endocarditis based on positive blood culture data in a sub-group of 




The data, analytic methods and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure. However, these individual-
level data are available via application to NHS Information Services Scotland. 
 
Study design and data sources 
We conducted a consecutive retrospective individual patient linkage study across multiple 
national databases (Supplementary figure 1). In brief, Scottish hospital discharge codes were 
used to identify patients hospitalized with infective endocarditis. All episodes for patients aged 
≥20 years admitted between 01/01/1990 and 31/12/2014 identified as infective endocarditis 
were linked to the national hospitalization register (Scottish Morbidity Record 01) in Scotland. 
Incident cases of infective endocarditis identified from the national hospitalization register 
between 01/01/2008 and 31/12/2014 were additionally linked to positive blood culture data 
derived from individual patients derived through linkage with the national microbiology 
surveillance database (Electronic Communication of Surveillance in Scotland) 
(Supplementary text 1).  
 
Participants  
Incident episodes of infective endocarditis were identified from hospital inpatient records using 
the International Classification of Diseases (ICD) codes (Supplementary text 2). Based on our 
validation exercise, only patients with a diagnostic code for endocarditis in the first two 
positions were included (Supplementary text 3). A five year look-back period minimized the 
risk of recurrent episodes of infective endocarditis from being misclassified as incident cases 





For each patient hospitalization, we extracted age at hospitalization, sex, comorbidity and 
socio-economic status.  Socio-economic status was assessed via a national area-based measure 
of deprivation, the Scottish Index of Multiple Deprivation (SIMD). The SIMD is measured in 
quintiles with the fifth quintile being least deprived. In brief, SIMD identifies small 
geographical regions (each region related to postal [‘zip’] code and corresponding to 
approximately 750 residents) of material deprivation based on information derived from seven 
domains (income; employment; health; education, skills and training; geographic access to 
services; crime; and housing).13 Scores from each domain (which are themselves weighted 
according to their relative importance) are combined into an overall score, which in turn allows 
that area to be ranked. Scores and ranks based on SIMD have been used extensively in 
published epidemiological research from Scotland,14,15 including guiding primary prevention 
in Scotland.16 For our study, every patient enrolled in our cohort was assigned a SIMD quintile 
based on their individual SIMD rank at the time of their index admission. 
 
Patient comorbidities were defined using established ICD codes based on previous 
hospitalizations and procedures using a five year look-back period. For every case of infective 
endocarditis during the 25 year period from 1990 until 2014, we extracted the following 
comorbidity data: (history of) myocardial infarction, cerebrovascular disease, heart failure 
hospitalization, implanted cardiac device and cardiothoracic surgery (Supplementary text 2). 
From 2009 onwards, prescribing data were used to provide additional comorbidity 






Baseline characteristics of all hospitalizations were summarised by 5 calendar year groups from 
1990 to 2014 and in single calendar year groups from 2008 onwards. Baseline characteristics 
were also summarised by blood culture detail. Incident hospitalizations were summed by 
calendar year, age and sex. Mid-year population estimates for the general population in 
Scotland, stratified by age and sex, were obtained from National Records of Scotland. For 
people without incident infective endocarditis, person-time not at risk (attributable to incident 
infective endocarditis events) was also summed by the same stratifying variables. Within the 
levels of these stratifying variables, person-time for people with no infective endocarditis was 
obtained by subtracting the infective endocarditis person-time from the mid-year population 
estimates (Supplementary text 4). Outcomes consisted of mortality, stroke, heart failure and 
valve surgery at 30 days and 1 year following the index presentation. 
 
Modelling 
Generalized additive models were used to estimate trends in incidence and outcomes of 
infective endocarditis. For incidence rates, log link and Poisson error distribution were used 
with a scaling factor (quasi-Poisson) to allow for overdispersion. Incidence rates per annum 
were generated for the whole population and stratified by sex and age. For outcomes, 1 year 
mortality was the primary outcome and year of admission as the primary explanatory variable 
adjusted for age, sex, comorbidity and deprivation. For both estimation of trends in the 
incidence rates and outcomes of infective endocarditis, models were fitted using non-
parametric smooth terms (penalized thin plate regression splines) for the year of admission. 
For the analysis of the association between 30 day and 1 year mortality and microbiology, 
logistic regression models were constructed adjusted for age, sex, deprivation and comorbidity.   
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An interrupted time series analysis17 was used to evaluate the incident rates of infective 
endocarditis before (2001 to 2007) and after (2008 to 2014) the introduction of new antibiotic 
prophylaxis guidelines from the National Institute of Health and Care Excellence (NICE) 
(Supplementary text 6).18 A sensitivity analysis was also performed to evaluate the effect of 
restricting the cohort to the first diagnostic coding position. Statistical analysis was performed 
in R, Version 3.5.1 (Vienna, Austria).  
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Results 
Across 7,513 individual patients, there were 7,638 hospitalizations (mean age 65±17 years, 
51% females) with incident infective endocarditis from 1990 to 2014 in Scotland (Table 1; 
Supplementary table 1). 
 
The estimated crude rate of hospitalization increased from 5.3 per 100,000 (95% confidence 
interval [CI] 4.8 - 5.9) to 8.6 per 100,000 (95% CI 8.1 - 9.1) between 1990 and 1995 but 
remained stable thereafter with the incident rate in 2014 of 8.1 per 100,000 (95% CI 7.5 - 8.9) 
(Figure 1a; Supplementary table 2). Similar relative changes were seen in the incidence of 
infective endocarditis in our sensitivity analysis restricting the cohort to the first diagnostic 
code position (Supplementary figure 2). Estimated rates comparing men and women also 
appeared similar up until 2003, but appeared to diverge thereafter (Supplementary figure 3; 
Supplementary table 2).  
 
When stratified by age, patients >80 years showed a marked increase in the incidence of 
infective endocarditis rising from 17.7 per 100,000 [95% CI 13.4 - 23.3] in 1990 to 37.9 per 
100,000 [95% CI 31.5 - 45.5] in 2014 (Figure 1b; Supplementary table 3). In contrast, in the 
60-79 year age group, the estimated rate was 11.5 per 100,000 (95% CI 10.1 - 13.2) in 1990 
peaking at 20.6 per 100,000 (95% CI 19.2 - 22.0) in 1996 before steadily decreasing to 12.6 
per 100,000 (95% CI 11.1 - 14.3) in 2014. In the younger age groups, the incident rates of 
endocarditis appeared relatively unchanged (Figure 1b; Supplementary table 3). There was 
no change in the incident rate of infective endocarditis following implementation of NICE 
guidelines on antibiotic prophylaxis (relative risk of change 1.06, 95% CI 0.94 - 1.20, p=0.420) 
(Figure 2).    
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During the study period, 32% (2,426/7,638) of patients admitted to hospital with infective 
endocarditis died within one year of admission. Both age and sex influenced 1 year mortality, 
adjusted for deprivation and comorbidity (Supplementary table 4). Age-adjusted and sex-
stratified predicted case fatality rates are shown in Supplementary figure 4 and Supplementary 
table 5. For a 65 year-old female, the predicted risk of one year mortality reduced from 27.3% 
in 1990 (95% CI 24.6% - 30.2%) to 23.7% (95% CI 21.0% - 26.6%) in 2014. Similarly, for a 
65 year-old male, the risk of one year death fell from 30.7% (95% CI 27.7% - 33.8%) to 26.8% 
(95% CI 24.0 - 29.7%). Past history of cerebrovascular disease (adjusted odds ratio [OR] 1.28, 
95% CI 1.07 - 1.49), heart failure hospitalization (OR 2.09, 95% CI 1.96 - 2.22) and deprivation 
(OR 0.92, 95% CI 0.88 - 0.95 per unit increment in rank; rank 1 assigned as being most 
deprived and rank 5 as least deprived) were also associated with a higher risk of death at one 
year. 
 
Data on incident cases of infective endocarditis were available from 1990 to 2014. However, 
positive blood culture data were also available from 2008 until 2014. As such, the population 
with blood culture microbiology linkage consisted of 30% (2,267/7,638) of all hospitalizations 
(Table 2).  Positive blood cultures were recorded in 42% (950/2,267) of hospitalizations with 
the majority of the remainder being culture negative (defined as individuals in whom blood 
cultures yielded no organism or in whom no cultures were performed).  
 
From our validation exercise, 12.5% of patients with a clinical diagnosis of infective 
endocarditis did not have blood cultures taken (Supplementary text 3). At a national level, we 
could only link patient level data to positive microbiology using the Electronic Communication 
of Surveillance in Scotland registry. As such, it was neither possible to determine what 
proportion of the remaining 1,317 cases were associated with sterile blood cultures, nor what 
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proportion had no blood cultures performed.  However, extrapolating from our validation data, 
where 87.5% of all cases had blood cultures performed, we assume that the vast majority of 
the 1,317 cases also had blood cultures performed with a significant proportion yielding no 
growth.  
 
Staphylococcus (403/950, 42.4%), streptococcus (337/950, 35.5%) and enterococcus (85/950, 
8.9%) were the most common organisms identified (Supplementary figure 5). The majority of 
staphylococci were Staphylococcus aureus (301/403, 74.7%,). Across the years, positive 
microbiology rate increased from 34.7% in 2008 to 45.4% in 2014 (Supplementary figure 6). 
Several factors were associated with 30 day and 1 year mortality (Supplementary figure 7 and 
Figure 3, respectively). Compared to patients without positive blood cultures, those with 
Staphylococcus aureus and enterococcus were at the highest risk of 1 year mortality (OR 4.34 
[95% CI 3.12-6.05] and 3.41 [95% CI 2.04-5.70], respectively). 
 
In our sensitivity analysis restricting the cohort to the first diagnostic code position, positive 
blood cultures were identified in 63% (753/1,195) of patients (Supplementary figure 8). 
Similar to the primary analysis, those with Staphylococcus aureus and enterococcus were at 
the highest risk of 1 year mortality (OR 2.23 [95% CI 1.47 - 3.39] and 1.89 [95% CI 1.05 – 





In this nationwide population cohort study using individual patient-level data linkage, we make 
several important observations. First, while the estimated overall crude incidence of infective 
endocarditis has remained relatively stable from 1995 onwards. When stratified by age, there 
was a two-fold increase in incidence in the elderly but either decreasing or static rates in 
younger patients. Second, the adjusted case fatality rate following endocarditis remains high 
but has declined over the last 25 years. Following adjustment for age and comorbidity, men 
had overall higher case fatality rates than women. Third, less than half of all patients had 
positive blood cultures, with the overall positive blood culture rate increasing from 35% in 
2008 to just under half in 2014. Where a causative organism was identified, staphylococcus 
and streptococcus were the most common species. Fourth, compared to patients no positive 
blood cultures, patients with Staphylococcus aureus or enterococcus bacteremia had the highest 
risk of death. Finally, and perhaps of most clinical relevance, our analysis has shown that the 
2008 change in antibiotic prophylaxis guidelines in the United Kingdom has not resulted in a 
significant rise in incident cases of infective endocarditis.  
 
Population-based studies in endocarditis remain scarce with the majority of epidemiology 
extrapolated from hospital-based cohorts or cross-sectional studies.19, 20 Our dataset included 
cases of infective endocarditis over the last 25 years. Whilst we only had positive blood culture 
data for a fifth of this period, evaluating the overall period allowed us to investigate long-term 
trends in incidence of and outcomes following infective endocarditis. With the exception of 
recent large population-based time-series analyses evaluating the temporal incidence of 
endocarditis in England4,21 and United States,7, 22 the majority of studies are limited by sample 
size, consisting of fewer than one thousand patients.20 All of these studies are further limited 
by incomplete characterization of participant demographics and characteristics, including 
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comorbidity, case-fatality rates and microbiology. Using an established national linkage 
approach in Scotland,23, 24 we identified over 7,000 hospitalizations with a diagnosis of 
infective endocarditis and provide detailed individual patient-level information on baseline 
demographics, comorbidity burden, associated microbiology data and subsequent case fatality 
rates.     
 
As such, there are several strengths to our study. First, our approach ensured complete follow-
up in those patients who remained resident in Scotland during the study period. Indeed, similar 
linkages have already been used to deliver randomized clinical trials23, 25 and cohort studies24 
in Scotland.  Second, our cohort consisted of consecutive patients hospitalized with a 
diagnostic code for infective endocarditis, avoiding selection bias and ensuring that our study 
population was representative. Third, unlike previous administrative data assets utilising 
diagnostic coding data to determine culture status,7, 22 which may not have been restricted to 
blood stream infections, we have used primary patient-level data from Scottish microbiology 
laboratories to ensure accurate recording of positive blood culture status. Fourth, using source 
clinical data, we validated the accuracy of the diagnostic coding including code position and 
microbiology data using data from local microbiology laboratory information systems 
(ensuring consistency with the national microbiology surveillance systems across Scotland).  
 
Three relatively recent guideline updates have emerged from the National Institute of Health 
and Care Excellence18 in the United Kingdom, the American Heart Association (AHA)26 and 
the European Society of Cardiology.2 These guidelines have recommended either complete or 
partial cessation of antibiotic prophylaxis in patients at moderate or high risk of infective 
endocarditis. Subsequent analyses evaluating the incidence of infective endocarditis have 
shown contrasting results. In England, a significant reduction in antibiotic prescriptions and an 
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apparent rise in the incidence of endocarditis was observed following the introduction of 
changes to NICE guidelines.2,4 Similar results were noted in a US-based population comparing 
incidence before and after changes to antibiotic prophylaxis guidelines in 2007.7 In contrast, 
three studies from the United States showed no increase in incidence following changes to 
antibiotic prophylaxis guidelines.8,27,28 These studies, however, were either limited in terms of 
cohort size8 or evaluated incidence over a shorter time frame following the change in 
guidelines.27 Furthermore, small but well-characterized populations in the United States29 and 
France10 have also reported static incident rates. In our study, the crude incident rate of infective 
endocarditis increased in Scotland from 1990 until 1995 but remained relatively static 
thereafter, suggesting that changes to clinical guidelines regarding antibiotic prophylaxis were 
not associated with an adverse effect on the incidence of infective endocarditis in Scotland. 
 
We observed an important interaction between age and rates of endocarditis. The incidence in 
patients over the age of 80 increased two-fold, whilst remaining static or decreasing in younger 
populations. This striking increase in the elderly is multifactorial and most likely reflects 
changes in the incidence of degenerative valvular heart disease, a rise in the number of patients 
surviving with multiple comorbidities, an increase in the provision of invasive therapeutic 
interventions including implantable cardiac devices (pacemakers, defibrillators, closure 
devices and percutaneous valve technology)30 and hemodialysis,31 and more extensive 
investigations32 in frail, elderly patients. 
 
We report important differences in the microbiology of patients with infective endocarditis 
compared to many studies in the existing literature. In our study, with linkage to a robust 
national microbiology laboratory blood culture dataset, no causative organism was identified 
in the majority (57%) of patients. In the published literature, culture-negative endocarditis 
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varied from 15% to 60% across both hospital-based cohorts20, 33 and population registries based 
primarily on US populations.7, 22, 34 Several reasons might explain our low culture positive 
rates. First, we defined infective endocarditis using diagnostic coding. Whilst this is more 
sensitive and eliminated selection bias, it is possible that the lower rates of culture positive 
cases reflect lower specificity by including some patients with lower probability of infective 
endocarditis. We validated the accuracy of the diagnostic coding using an in-depth health 
record review of nearly 400 cases. Restricting the patient population to the first two diagnostic 
positions gave an overall positive predictive value for definite or probable diagnosis of 
infective endocarditis of 88%. As such, case ascertainment bias due to coding error is unlikely 
to have made a significant contribution. Second, from 2009 to 2012, three laboratories did not 
provide complete microbiology data for national linkage. These laboratories were small and 
served <1.5% of the Scottish population and would therefore have a negligible effect on the 
rates of positive blood cultures. Third, across most hospitalized cohorts of patients with 
infective endocarditis, cases were identified by the attending clinician.35 A high culture positive 
rate in these cohorts may therefore reflect selection bias towards patients with positive blood 
cultures.11 Across population registry data, the culture-negative rates were higher7, 22 with 
similar rates to those observed in Scotland.34 Fifth, across both population registries7, 22 and 
some hospital-based cohorts,36 culture status was not restricted to blood cultures but also 
included tissue cultures including valves and serological tests, invariably increasing the rates 
of culture positive diagnosis.36 Reassuringly, where positive blood cultures were obtained in 
our cohort, streptococcus and staphylococcus were the most commonly identified pathogens, 
consistent with the wider literature.37, 38 Finally, we noticed a relative rise of 16% in the 
proportion of patients with culture positive infective endocarditis from 2008 to 2014. This 
observation likely reflects more judicious timing of administration of antibiotic treatment and 
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ensuring blood cultures are taken prior to initiation of therapy; clinical practice that has been 
emphasized in recent international guidelines.39    
 
Across the study cohort, crude temporal mortality rates at one year remained stable, ranging 
from 27% to 33%. However, after adjustment, we observed a steady reduction in mortality. A 
recent large US based study showed a similar relationship with decreasing mortality over a 
similar time period22 whilst others have shown little or no change in case fatality.4, 40 Positive 
microbiology was independently associated with poorer outcomes. Staphylococcus aureus 
bacteremia was independently associated with a four-fold increased mortality rate at 30 days 
and one year. In contrast, the magnitude of association for enterococcus bacteremia changed 
from a two-fold increased risk at 30 days to three-fold increased risk at one year. This 
observation likely reflects a frailer and older population that is more susceptible to 
enterococcus bacteremia41, 42 and at higher risk of medium- to long-term mortality.43-45     
 
Limitations   
There are several limitations to our study. First, index cases and comorbidity were defined 
using administrative datasets, which are subject to inaccurate coding. However, we improved 
coding specificity for infective endocarditis using data from our validation work. To ensure a 
reasonable balance between specificity and sensitivity, we included all hospitalizations with a 
diagnostic code appearing in the first two (of six) positions only. Restricting the population to 
the first diagnostic position markedly reduced the sensitivity for infective endocarditis in 
previous literature.22 Second, for our validation exercise, the diagnosis of infective endocarditis 
was based on a clinician documented diagnosis of infective endocarditis. Whilst we 
acknowledge that the Modified Duke Criteria represent the ‘gold standard’ for defining cases 
of infective endocarditis,2 unfortunately the vast majority of clinicians did not reference these 
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criteria in clinical notes entered on electronic patient records. For example, the presence or 
absence of physical exam findings relevant to the minor criteria (e.g. vascular or immunologic 
phenomena) were frequently not documented. After careful consideration of the impact of 
these missing data and the potential for introducing significant bias, our research team elected 
to employ a more pragmatic approach with ‘true’ cases of infective endocarditis defined as 
those clinically documented and treated as infected endocarditis. Third, we could not 
differentiate patients with blood culture negative infective endocarditis from those patients in 
whom blood cultures were not performed. From our validation work, we suspect that just over 
10% of all patients will fall into the latter category. Fourth, whilst we have attempted to address 
the majority of confounders, residual unmeasured confounding may have affected the trends 




We report important temporal changes in patients with infective endocarditis in the Scottish 
population over the past 25 years. The crude incidence of infective endocarditis increased from 
1990 to 1995 but has remained relatively static thereafter. Importantly, the incidence has 
increased two-fold in the elderly. Both short- and long-term adjusted case fatality rates of 
infective endocarditis have shown a steady decrease over the last 25 years. Finally, and most 
interestingly, the majority of patients with infective endocarditis in our cohort did not have 
positive blood cultures. In those patients with positive microbiology, staphylococcus and 
enterococcus conferred the highest risk of all-cause mortality. Our data highlight that infective 
endocarditis remains a lethal condition, especially in the elderly. We also demonstrate the 
importance of microbiology data for prognostication, not only for in-hospital mortality, but 
also for medium-term outcomes. As such, our data further support the multi-disciplinary 
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integration of cardiology, microbiology and infectious disease teams as advocated by 
international guidelines to optimize diagnosis and patient care.2   
 18 
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Figures and tables 
 
Figure 1: Estimated incidence rate per 100,000 in the population (A) and stratified by age 
groups (B).  
 
Blue circles in A represent the absolute crude rates with the size of the circles proportional to 
the absolute count. The solid blue line represents the estimated incident rate from generalized 
additive modelling using the Poisson distribution. The dashed blue lines represent the 
corresponding upper and lower 95% confidence interval bounds. 
 
Figure 2: Plot showing the observed incident rates per 100,000 by year of hospitalization 
(black dots), in relation to the introduction of national antibiotic prophylaxis guidelines. 
 
The shaded grey box indicates introduction of NICE antibiotic prophylaxis guidelines. The 
black line shows the predicted incident rate using the model described in Supplementary text 
6, incorporating the change in guidelines from 2008 onwards. The overlying red line shows 
the predicted incident rate assuming the counterfactual of no change in antibiotic prophylaxis 
guidelines in 2008.  
 
Figure 3: Forest plot showing odds ratio from logistic regression evaluating the association 
between all-cause mortality at 1 year and patient demographics, comorbidity and microbiology. 
 
Table 1: Baseline characteristics and outcomes in patients hospitalized with infective 
endocarditis, stratified by 5 year calendar groups. 
 
Table 2: Baseline characteristics and outcomes in patients hospitalized with infective 
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 Calendar years in 5 year groups 
1990 - 1994 1995 - 1999 2000 - 2004 2005 - 2009 2010 - 2014 
Number of patients, n 1379 1642 1464 1537 1616 
Baseline characteristics      
Age, years (SD) 62.10 (17.25) 64.62 (16.34) 65.32 (17.59) 66.01 (16.92) 66.56 (17.96) 
Women, n (%)   771 (55.9)    855 (52.1)    775 (52.9)    751 (48.9)    768 (47.5)  
Deprivation index, n (%)      
Rank 1 (most deprived)   402 (29.4)    404 (24.7)    387 (26.6)    369 (24.1)    365 (22.7)  
Rank 2   327 (23.9)    363 (22.2)    351 (24.1)    326 (21.3)    376 (23.4)  
Rank 3   233 (17.1)    310 (19.0)    257 (17.7)    318 (20.7)    319 (19.9)  
Rank 4   223 (16.3)    276 (16.9)    254 (17.5)    273 (17.8)    274 (17.1)  
Rank 5 (least deprived)   181 (13.3)    282 (17.2)    205 (14.1)    248 (16.2)    271 (16.9)  
Previous medical conditions/interventions      
Myocardial infarction, n (%)    59 ( 4.3)     89 ( 5.4)     60 ( 4.1)     65 ( 4.2)     80 ( 5.0)  
Cerebrovascular disease, n (%)    68 ( 4.9)     108 ( 6.6)     83 ( 5.7)     82 ( 5.3)     75 ( 4.6)  
Heart failure hospitalization, n (%)   220 (16.0)    315 (19.2)    251 (17.1)    206 (13.4)    173 (10.7)  
Cardiac device, n (%)    25 ( 1.8)     45 ( 2.7)     48 ( 3.3)     42 ( 2.7)     48 ( 3.0)  
Prior cardiac valvular surgery, n (%)   151 (10.9)    161 ( 9.8)    136 ( 9.3)    119 ( 7.7)    130 ( 8.0)  
Outcomes at 30 days           
All-cause death, n (%)  196 (14.2)   233 (14.2)   231 (15.8)   198 (12.9)   223 (13.8)  
Heart failure hospitalization, n (%)   41 ( 3.0)    58 ( 3.5)    75 ( 5.1)    84 ( 5.5)    74 ( 4.6)  
Subsequent valve surgery, n (%)   64 ( 4.6)    77 ( 4.7)    66 ( 4.5)    73 ( 4.7)    86 ( 5.3)  
Outcomes at 1 year      
All-cause death, n (%)  435 (31.5)   515 (31.4)   490 (33.5)   486 (31.6)   500 (30.9)  
Heart failure hospitalization, n (%)  189 (13.7)   215 (13.1)   177 (12.1)   191 (12.4)   158 ( 9.8)  














Streptococcus Enterococcus Polymicrobial 
/ other 
Number of patients, n 1317 301 102 337 85 125 
Age, years 69.5 (16.9) 58.92 (19.09) 65.41 (14.95) 63.35 (17.39) 70.28 (13.06) 60.83 (19.22) 
Women, n (%)   735 (55.8)    113 (37.5)     40 (39.2)    107 (31.8)     29 (34.1)     53 (42.4)  
Deprivation index, n (%)       
Rank 1 (most deprived)   279 (21.3)     92 (30.7)     21 (20.6)     73 (21.7)     29 (34.1)     33 (26.6)  
Rank 2   320 (24.5)     69 (23.0)     23 (22.5)     47 (14.0)     21 (24.7)     40 (32.3)  
Rank 3   286 (21.9)     54 (18.0)     17 (16.7)     70 (20.8)     13 (15.3)     17 (13.7)  
Rank 4   218 (16.7)     44 (14.7)     23 (22.5)     70 (20.8)     11 (12.9)     20 (16.1)  
Rank 5 (least deprived)   205 (15.7)     41 (13.7)     18 (17.6)     76 (22.6)     11 (12.9)     14 (11.3)  
Previous medical conditions/interventions       
Myocardial infarction, n (%)    68 ( 5.2)     12 ( 4.0)      8 ( 7.8)     17 ( 5.0)  < 5     5 ( 4.0)  
Cerebrovascular disease, n (%)    62 ( 4.7)     13 ( 4.3)      7 ( 6.9)     15 ( 4.5)      9 (10.6)      6 ( 4.8)  
Heart failure hospitalization, n (%)   157 (11.9)     29 ( 9.6)     14 (13.7)     34 (10.1)      6 ( 7.1)     18 (14.4)  
Cardiac device, n (%)    27 ( 2.1)     12 ( 4.0)      8 ( 7.8)  < 5 < 5     6 ( 4.8)  
Cardiac valve surgery, n (%)    71 ( 5.4)     17 ( 5.6)     27 (26.5)     30 ( 8.9)     10 (11.8)     16 (12.8)  
Chronic respiratory disease, n (%)*   195 (19.1)     36 (14.8)     13 (15.5)     58 (20.7)     16 (22.5)     16 (16.2)  
Diabetes mellitus, n (%)*   133 (13.0)     35 (14.4)     22 (26.2)     30 (10.7)     11 (15.5)     18 (18.2)  
Outcomes at 30 days            
All-cause death, n (%)  130 ( 9.9)   130 ( 9.9)   71 (23.6)   26 (25.5)   49 (14.5)  12 (14.1)  
Heart failure hospitalization, n (%)   78 ( 6.0)    6 ( 2.0)  < 5  15 ( 4.5)  < 5   7 ( 5.6)  
Subsequent valve surgery, n (%)   23 ( 1.8)   35 (11.6)    5 ( 4.9)   46 (13.6)   5 ( 5.9)    7 ( 5.6)  
Outcomes at 1 year       
All-cause death, n (%) 336 (25.5)  133 (44.2)   46 (45.1)   99 (29.4)  43 (50.6)   41 (32.8)  
Heart failure hospitalization, n (%) 159 (12.1)   18 ( 6.0)   10 ( 9.8)   33 ( 9.8)   6 ( 7.1)   16 (12.8)  
Subsequent valve surgery, n (%)   87 ( 6.6)   54 (17.9)   18 (17.6)   85 (25.2)   9 (10.6)   19 (15.2)  
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Supplementary figure 1: Map summarising linkage of national data assets to define the study population and subsequent longitudinal follow 
up. Nomenclature: Anonymised patient ID- Community Health Index (CHI) number; Community prescriptions and dispensing- Prescribing 
Information System (PIS); National blood culture repository- Electronic communication of surveillance in Scotland (ECOSS); Scottish 








Supplementary figure 2: Sensitivity analysis restricting to diagnostic coding in position one (primary diagnosis). Estimated incidence rate per 












Supplementary figure 5: Positive blood culture microbiology stratified by species  
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Supplementary figure 9: Sensitivity analysis restricting to diagnostic coding in position one. Forest plot showing association of microbiology 





Supplementary text 1: Descriptions and sources of national data assets used for individual 
patient level linkage 
 
Scottish hospitalization record  
 
Scottish hospitalizations from infective endocarditis were defined from the Scottish morbidity 
record 01 (SMR01) - General/Acute Inpatient & Day Case. SMR01 is an episode-based patient 
record relating to all inpatients and day cases discharged from non-obstetric and non-
psychiatric specialties. A record is generated when a patient completes an episode of inpatient 
or day case care. Data collected include patient identifiable and demographic details, episode 
management details and general clinical information. Currently diagnoses are recorded using 
the ICD-10 classification and operations are recorded using the OPCS-4 classification. Further 




Past history, operation codes and demographics were also derived from the Scottish Morbidity 
Record 01 and linked to incident cases of infective endocarditis. Subsequent hospitalizations 
based on ICD codes are further linked to incident cases of infective endocarditis identified. 
 
National Records of Scotland (NRS) 
   
The NRS covers all deaths in Scotland with approximately 55,000 deaths registered annually. 
The National Records of Scotland Death Records are linked with the NHS Scotland Scottish 
Morbidity Database which links together NHS Scotland inpatient, mental health and cancer 
registry datasets with the NRS Death Records. 
 
Death status, cause of death and date of death were linked to the patients defined as having 
incident infective endocarditis.  
 
Further information of the NRS death registry is available at 
https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=13 
 
Prescribing Information System (PIS) 
 
The Prescribing Information System (PIS) is the definitive data source for all prescribing 
relating to all medicines and their costs that are prescribed and dispensed in the community in 
Scotland. The information is supplied by Practitioner & Counter Fraud Services Division 
(P&CFS) who is responsible for the processing and pricing of all prescriptions dispensed in 
Scotland. Primary care physicians write the vast majority of these prescriptions, with the 
remainder written by other authorised prescribers such as nurses and dentists. Also included in 
the dataset are prescriptions written in hospitals that are dispensed in the community. Note that 
prescriptions dispensed within hospitals are not included.  
 
Both the diabetes and chronic lung disease status in our cohort were based on community 
prescribing data as per Supplementary table 5. Incident cases of endocarditis prescribed either 
anti-diabetic drugs or drugs for chronic lung disease with one year prior to hospitalization were 
defined as having the condition. Complete prescribing data was available from 2009. 
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Further information on the Prescribing Information System operational in Scotland is available 
at https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=9 
 
National microbiology register (Electronic Communication of Surveillance in Scotland 
[ECOSS]) 
 
The Scottish microbiology surveillance registry, or ‘Electronic Communication of Surveillance 
in Scotland’ (ECOSS) as it is termed by NHS National Services Scotland, was used in the 
present study to provide individual patient-level data on positive blood culture results (from 
diagnostic microbiology laboratories within NHS Scotland health boards and national 
reference laboratories) related to incident cases of infective endocarditis identified from 
SMR01 between 2008 and 2014. ECOSS is part of NHS Scotland’s Infection Intelligence 
Platform (IIP),1,2 which was set-up in response to the UK’s antimicrobial resistance (AMR) 
strategy (2013-2018) with the aim of providing “better access to and use of surveillance data”.3  
 
Data were first collected and recorded within ECOSS in 2007. The dataset is maintained by 
NHS National Services Scotland on behalf of Health Protection Scotland. ECOSS is updated 
monthly and, as of 2017, it contained approximately 29 million records of positive 
microbiology laboratory specimens from across Scotland.1 It provides data for numerous 
national clinical and research activities, audit projects and Scottish Government reports, 
including: the identification of cases of severe infectious disease, infectious disease outbreaks 
and the evaluation of longer term trends in the incidence of laboratory-reported infections; 
surveillance of episodes of Clostridium difficile infections, Escherichia coli bacteremia, 
Staphylococcus aureus bacteremia and surgical site infections.2 NHS National Services 
Scotland monitors the completeness and accuracy of ECOSS data through its ‘Data Monitoring 
and Support Service’.1 Further, NHS National Services Scotland routinely informs data users 
of any problems affecting the accuracy or assurance of these data. 
 
In the present study, causative organisms were defined as those identified within 90 days on 
either side of the index admission date. Using this timeframe, 950 cases of infective 
endocarditis were associated with positive microbiological results. 
 
Polymicrobial status was defined specifically is more than one causative organism was 
identified on the same culture date. If more than one causative organism was identified on 
differing dates, then the organism identified closest to the index admission date was assigned 
as the causative organism.  
 
Near complete blood culture microbiology data were available from 2008. Three small Scottish 
laboratories did not provide complete data.  These laboratories were as follows:  
- Shetland (GIL:BAN) – no data for 2009-2011; for 2012 we only received two blood 
culture reports 
- Western Isles (WES:LES) – no data for 2009-2010 
- Orkney (ORK:BAL) – 2009 only one blood culture report received; no data for 2010  
 
Overall these laboratories served <1.5% of the Scottish Population and would therefore have a 
negligible effect on the rates of non-positive blood cultures observed. 
 
More information on the ECOSS data system is available at https://www.hps.scot.nhs.uk/data/ 
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Approvals for use of data 
 
Access to the data was approved by the NHS Scotland Public Benefit and Privacy Panel and in 
accordance with the Declaration of Helsinki. As the analysis used routinely collected and 




Supplementary text 2: ICD-9 and ICD-10 code identifiers employed to identify cases of 
infective endocarditis from SMR01 dataset 
 
Co-morbidity Relevant ICD codes 
Infective endocarditis  
ICD-9 421.1, 424.91, 424.90, 424.99 
ICD-10 I33, I38, I39 
Myocardial infarction  
ICD-9 413 
ICD-10 I21, I22 
Cerebrovascular disease  
ICD9 430 - 438 
ICD10 I60-I69 
Heart failure  
ICD-9 428 
ICD-10 I50 
Valve surgery  
OPCS K04 - K12, K14, K17 - K34 
Cardiac device  
OPCS K59 - K61 
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Supplementary text 3: Validation of SMR01 ICD-9 and ICD-10 coding for diagnosis and 
microbiology of infective endocarditis 
 
Electronic hospital records of 396 episodes of suspected infective endocarditis dating from a 
5-year period (2014-2018) were manually reviewed by two authors (PG and JH) as part of the 
validation exercise. The electronic records were reviewed to determine if the diagnosis of 
infective endocarditis was accurate.  
 
 
Thereafter, electronic hospital records of 200 episodes of suspected infective endocarditis with 
a diagnostic code position of 1-3 and 168 episodes of suspected infective endocarditis with a 
diagnostic code position of 1-2 were reviewed in order to determine if blood cultures had been 
sent within 6 months of the index diagnosis from the admitting hospital. 
 
 
Clinical definition of infective endocarditis in our validation exercise 
Although the Modified Duke Criteria (MDC) represent the ‘gold standard’ for defining cases 
of infective endocarditis, we were unable to employ the MDC reliably in our validation 
exercise. This was partly because the vast majority of clinicians did not reference the MDC in 
their documentation. Further, the presence or absence of key physical exam findings relevant 
to the minor criteria (e.g. vascular or immunologic phenomena) were frequently not 
SMR01 diagnostic code position Positive predictive value, % (95% CI) 
Main condition only (1) 97.1 (95.0 to 99.0) 
Main condition and second diagnostic code position (1-2) 88.6 (84.7 to 92.5) 
Main condition, second and third diagnostic code positions (1-3) 79.6 (75.7 to 83.5) 
Any diagnostic code position (1-6) 67.9 (64.0 to 71.8) 
SMR01 diagnostic code position Overall blood cultures sent, n (%) 
Main condition and second diagnostic code position (1-2) 147 (87.5) 
SMR01 diagnostic code position Organism grown in blood cultures, n (%) 
Main condition and second diagnostic code position (1-2) 89 (52.9) 
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documented in patient records. After careful consideration of the impact of these missing data 
and the potential for introducing significant bias if we persisted with the MDC to define cases 
of infective endocarditis, our research team elected to employ a more pragmatic approach in 
the definition of infective endocarditis from electronic clinical records. The definition to define 
endocarditis has been summarised below. 
 
Definition 
True IE: Clinician diagnosis of IE documented in patient notes and patient treated as IE.  
No IE: No clinician diagnosis of IE documented in patient notes and/or patient not treated as 
IE. 
 
As mentioned above our validation work included all local cases of infective endocarditis from 
2014 until 2018 (n=396). Of these, infective endocarditis was the first or second diagnostic 
code in 67% (264/396) of hospitalizations, and the first diagnostic code in 53% (208/396) of 
hospitalizations during this period. Confirming infective endocarditis based on the above 
definition and a diagnostic code position of one or two provided an overall positive predictive 
value of 88.6%. The table below summarises our validation work stratified by clinician 
adjudicated diagnosis of infective endocarditis and diagnostic position: 
 
Certainty of infective 
endocarditis (IE) diagnosis 
SMR01 diagnostic 
code position 1, n (%) 
SMR01 diagnostic code 
positions 1 and 2, n (%) 
True IE 202/208 (97.1%) 234/264 (88.6%) 




Supplementary text 4: Description of 5 year lookback period and calculation of person-time 
 
Lookback 
The schematic below demonstrates an example of how the 5-year lookback period was 
employed in the period between 2000 and 2015 (inclusive) to identify incident events of 
infective endocarditis in three exemplar patients (patients A, B and C). The total incident count 
for each year is shown in the final column. Where a patient has been admitted with an episode 
of infective endocarditis, a ‘1’ appears in the ‘Admission’ column. If no infective endocarditis 
event has occurred in the 5-years prior (i.e. the ‘lookback’ period, as indicated by the light grey 




Patient A Patient B Patient C Total 
incident 
events Admission Incident Admission Incident Admission Incident 
2000 0 0 0 0 0 0 0 
2001 0 0 0 0 0 0 0 
2002 0 0 0 0 0 0 0 
2003 0 0 0 0 0 0 0 
2004 0 0 0 0 0 0 0 
2005 1 1 0 0 1 1 2 
2006 1 0 1 1 0 0 1 
2007 0 0 0 0 1 0 0 
2008 0 0 0 0 0 0 0 
2009 1 0 0 0 0 0 0 
2010 0 0 0 0 0 0 0 
2011 0 0 0 0 0 0 0 
2012 0 0 0 0 0 0 0 
2013 0 0 0 0 1 1 1 
2014 0 0 0 0 0 0 0 
2015 1 1 1 1 1 0 2 
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Person-time calculation 
The schematic below demonstrates an example across three patients on how the person-time 
was calculated. 
 
Year POP P1 P2 P3 PT 
2004 190 0 1 1 189 
2005 190 0 1 1 189 
2006 190 0 1 0 188 
2007 190 0 1 0 188 
2008 190 0 1 0 188 
2009 190 1 1 0 189 
2010 185 1 1 0 184 
2011 185 1 0 1 184 
2012 185 1 0 1 184 
2013 185 1 0 1 184 
2014 185 1 0 1 184 
 
POP refers to the mid-year estimate for the population (based on National Records Scotland 
census data and mid-year estimation modelling). P1, P2 and P3 refers to the person-time for 
each of the 3 patients with incident infective endocarditis. Patient 1 had an admission in 2004, 
they were not eligible to have another incident event within 5 years, and so the person-time for 
each of these periods is removed. Patient 2 had an incident event in 2011 and so only 
contributed 7 person-years. Patient 3 had an event in 2006 which was not incident, and as a 
consequence did not contribute to the period from 2006 to 2010 (inclusive). 
 
The person-time for each year, within each stratum, is therefore calculated as follows: 
P T = POP  − N + p1 + p2 + p3 + ...pn where N refers to the total number of individuals with 





Supplementary text 5: Use of ATC coding to determine comorbidity status 
 
  
Comorbidity Relevant class of drug  (British National Formulary 62) 
Chapter and section in 
the British National 
Formulary 
Chronic respiratory disease Respiratory system: all drugs Chapter 3 
Diabetes mellitus Endocrine system: drugs used in diabetes Chapter 6, section 6.1 
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Supplementary text 6: Details of interrupted time series analysis 
 
To evaluate any change in the incidence of infective endocarditis before and after introduction 
of guidelines on antibiotic prophylaxis published by the National Institute of Health and Care 
Excellence, an interrupted time series analysis model was created.  
 
We chose a step-change model. A Poisson model was used as we were predicting count data. 
We modelled the count data directly (rather than the rate which doesn't follow a Poisson 
distribution), using the person-time (log transformed) as an offset variable in order to transform 
back to rates. In order to account for overdispersion we used a quasipoisson model (allowing 
the variance to be proportional rather than equal to the mean). 
 
The following model was created with corresponding output: 
 
model <- glm(count ~ offset(log(person_time)) + guidelines + year + guidelines*year, 
family=quasi-poisson, data) 
 
Term estimate std.error statistic p-value 
(Intercept) -6.7862 25.2561 -0.2687 0.794 
Guidelines 0.3997 34.9581 0.0114 0.991 
Year -0.0014 0.0126 -0.1082 0.916 
Guidelines*Year -0.0002 0.0174 -0.0098 0.992 
 
 
The plot below shows no auto correlation removing the linear dependence of the lags using the 








Supplementary table 1: Baseline characteristics and short- and long-term outcomes stratified by single calendar years from 2008 to 2014 
 
Single-year groups 
2008 2009 2010 2011 2012 2013 2014 
Number of patients, n 340 311 317 312 315 311 361 
Age, years 66.2 (17.0) 66.8 (16.9) 65.9 (17.6) 67.5 (18.4) 66.5 (17.1) 67.7 (18.2) 65.4 (18.5) 
Women, n (%)   167 (49.1)    142 (45.7)    144 (45.4)    151 (48.4)    151 (47.9)    160 (51.4)    162 (44.9)  
Scottish index of multiple deprivation 
(SIMD) index, n (%)        
Rank 1 (most deprived)    80 (23.5)     82 (26.5)     72 (22.7)     69 (22.4)     66 (21.2)     72 (23.3)     86 (24.0)  
Rank 2    71 (20.9)     73 (23.5)     65 (20.5)     79 (25.6)     82 (26.3)     72 (23.3)     78 (21.7)  
Rank 3    77 (22.6)     61 (19.7)     68 (21.5)     64 (20.8)     59 (18.9)     50 (16.2)     78 (21.7)  
Rank 4    62 (18.2)     50 (16.1)     64 (20.2)     47 (15.3)     47 (15.1)     58 (18.8)     58 (16.2)  
Rank 5 (least deprived)    50 (14.7)     44 (14.2)     48 (15.1)     49 (15.9)     58 (18.6)     57 (18.4)     59 (16.4)  
Previous medical conditions / 
interventions        
Myocardial infarction, n (%)    15 ( 4.4)     18 ( 5.8)     16 ( 5.0)     21 ( 6.7)     14 ( 4.4)     14 ( 4.5)     15 ( 4.2)  
Cerebrovascular disease, n (%)    18 ( 5.3)     19 ( 6.1)     16 ( 5.0)     15 ( 4.8)     14 ( 3.4)     17 ( 5.5)     13 ( 3.6)  
Heart failure hospitalization, n (%)    39 (11.5)     46 (14.8)     35 (11.0)     45 (14.4)     31 ( 9.8)     32 (10.3)     30 ( 8.3)  
Cardiac device, n (%) < 5     6 ( 1.9)     10 ( 3.2)     10 ( 3.2)      9 ( 2.9)      8 ( 2.6)     11 ( 3.0)  
Cardiac valvular surgery, n (%)    15 ( 4.4)     26 ( 8.4)     35 (11.0)     29 ( 9.3)     22 ( 7.0)     22 ( 7.1)     22 ( 6.1)  
Chronic respiratory disease, n (%) -    42 (23.1)     69 (21.8)     51 (16.3)     56 (17.8)     51 (16.4)     65 (18.0)  
Diabetes mellitus, n (%) -    26 (14.3)     38 (12.0)     39 (12.5)     50 (15.9)     41 (13.2)     55 (15.2)  
Outcomes at 30 days             
All-cause death, n (%)  48 (14.1)   30 ( 9.6)   51 (16.1)   54 (17.3)   39 (12.4)   32 (10.3)   47 (13.0)  
Heart failure hospitalization, n (%)  20 ( 5.9)   20 ( 6.4)   18 ( 5.7)   14 ( 4.5)   13 ( 4.1)   17 ( 5.5)   12 ( 3.3)  
Valve surgery, n (%)  20 ( 5.9)   15 ( 4.8)   20 ( 6.3)   15 ( 4.8)   12 ( 3.8)   17 ( 5.5)   22 ( 6.1)  
Outcomes at 1 year        
All-cause death, n (%) 114 (33.5)   84 (27.0)   99 (31.2)   96 (30.8)   97 (30.8)   98 (31.5)  110 (30.5)  
Heart failure hospitalization, n (%)  42 (12.4)   42 (13.5)   35 (11.0)   35 (11.2)   33 (10.5)   29 ( 9.3)   26 ( 7.2)  
Valve surgery, n (%)  48 (14.1)   43 (13.8)   49 (15.5)   31 ( 9.9)   29 ( 9.2)   34 (10.9)   38 (10.5)  
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Supplementary table 2: Count data and estimated incidence rate per 100,000 stratified by year and sex 
 
Year 
Number of cases, n Estimated crude incidence rate per 100,000 
Overall Males Females Overall Lower  Upper  Males Lower  Upper  Females Lower  Upper  95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 
1990 201 100 101 5.34 4.80 5.94 5.62 4.87 6.48 5.28 4.54 6.15 
1991 225 106 119 6.46 6.05 6.89 6.26 5.71 6.87 6.62 6.03 7.28 
1992 318 130 188 7.53 7.08 8.02 6.91 6.34 7.53 7.95 7.29 8.66 
1993 305 135 170 8.28 7.80 8.79 7.49 6.90 8.14 8.84 8.14 9.59 
1994 330 137 193 8.59 8.13 9.08 7.98 7.39 8.63 9.09 8.41 9.82 
1995 333 165 168 8.63 8.14 9.14 8.37 7.75 9.05 8.90 8.22 9.64 
1996 326 143 183 8.58 8.11 9.07 8.63 8.01 9.31 8.59 7.94 9.29 
1997 314 156 158 8.51 8.05 9.00 8.71 8.08 9.38 8.37 7.73 9.06 
1998 326 164 162 8.40 7.93 8.90 8.55 7.92 9.24 8.25 7.60 8.95 
1999 330 152 178 8.21 7.76 8.68 8.24 7.63 8.89 8.15 7.52 8.82 
2000 291 130 161 7.94 7.49 8.41 7.87 7.28 8.51 7.98 7.35 8.66 
2001 291 138 153 7.66 7.22 8.13 7.56 6.99 8.19 7.75 7.13 8.42 
2002 278 131 147 7.41 6.99 7.86 7.35 6.79 7.95 7.48 6.88 8.12 
2003 303 144 159 7.22 6.80 7.67 7.24 6.68 7.84 7.23 6.64 7.88 
2004 272 130 142 7.11 6.70 7.56 7.24 6.68 7.84 7.06 6.48 7.69 
2005 264 119 145 7.14 6.73 7.57 7.41 6.86 8.01 6.97 6.41 7.59 
2006 282 153 129 7.32 6.89 7.77 7.77 7.19 8.40 6.96 6.38 7.59 
2007 314 160 154 7.60 7.18 8.06 8.24 7.65 8.88 6.98 6.42 7.60 
2008 332 169 163 7.83 7.40 8.29 8.61 8.00 9.27 6.99 6.42 7.61 
2009 302 164 138 7.84 7.39 8.31 8.66 8.04 9.33 6.95 6.37 7.58 
2010 314 171 143 7.61 7.20 8.05 8.40 7.81 9.03 6.87 6.32 7.47 
2011 302 155 147 7.36 6.94 7.81 8.08 7.49 8.72 6.82 6.25 7.44 
2012 307 160 147 7.32 6.89 7.78 8.00 7.40 8.64 6.87 6.29 7.51 
2013 302 144 158 7.60 7.19 8.05 8.29 7.69 8.94 7.05 6.47 7.68 









Supplementary table 3: Count data and estimated incidence rate per 100,000 stratified by year and age group 
 
Estimated crude incidence rate per 100,000 
Year 

























1990 2.27 2.04 2.51 4.70 3.93 5.63 11.50 10.01 13.21 17.66 13.36 23.32 
1991 2.27 2.06 2.50 5.03 4.46 5.69 13.56 12.37 14.87 20.06 16.22 24.80 
1992 2.28 2.08 2.49 5.35 4.80 5.96 15.78 14.59 17.08 22.55 18.99 26.78 
1993 2.28 2.10 2.48 5.58 5.02 6.20 17.87 16.58 19.25 24.89 21.40 28.94 
1994 2.29 2.11 2.47 5.67 5.11 6.28 19.48 18.14 20.91 26.90 23.35 30.98 
1995 2.29 2.13 2.47 5.57 5.02 6.18 20.39 19.00 21.88 28.56 24.89 32.76 
1996 2.30 2.14 2.46 5.33 4.81 5.91 20.56 19.19 22.02 29.93 26.17 34.22 
1997 2.30 2.16 2.45 5.02 4.52 5.57 20.10 18.76 21.54 31.03 27.20 35.40 
1998 2.31 2.17 2.45 4.72 4.24 5.25 19.21 17.90 20.62 31.85 27.97 36.26 
1999 2.31 2.18 2.45 4.46 4.01 4.97 18.09 16.85 19.42 32.34 28.47 36.74 
2000 2.32 2.19 2.45 4.27 3.82 4.76 16.94 15.74 18.22 32.54 28.69 36.92 
2001 2.32 2.20 2.45 4.10 3.67 4.58 15.92 14.77 17.16 32.52 28.70 36.84 
2002 2.33 2.20 2.45 3.96 3.55 4.43 15.17 14.06 16.35 32.35 28.59 36.59 
2003 2.33 2.21 2.46 3.86 3.45 4.32 14.74 13.65 15.92 32.09 28.38 36.29 
2004 2.34 2.21 2.47 3.81 3.41 4.26 14.66 13.58 15.82 31.82 28.16 35.95 
2005 2.34 2.21 2.48 3.83 3.43 4.27 14.84 13.76 16.00 31.63 28.02 35.71 
2006 2.35 2.20 2.50 3.89 3.49 4.35 15.13 14.03 16.32 31.65 28.04 35.73 
2007 2.35 2.20 2.51 3.97 3.56 4.42 15.34 14.24 16.53 31.94 28.32 36.02 
2008 2.36 2.19 2.53 3.99 3.58 4.45 15.28 14.19 16.46 32.48 28.82 36.60 
2009 2.36 2.19 2.55 3.95 3.54 4.41 14.91 13.82 16.07 33.18 29.46 37.37 
2010 2.37 2.18 2.57 3.89 3.49 4.34 14.31 13.27 15.43 33.96 30.22 38.15 
2011 2.37 2.17 2.59 3.89 3.48 4.34 13.68 12.66 14.79 34.78 31.00 39.03 
2012 2.38 2.17 2.61 4.00 3.58 4.46 13.17 12.17 14.25 35.69 31.72 40.17 
2013 2.38 2.16 2.63 4.24 3.78 4.77 12.82 11.77 13.97 36.72 32.06 42.07 




Supplementary table 4: Model coefficients from generalized additive model evaluating all-cause mortality by calendar year, adjusted for age 
and comorbidity 
  
 Estimate Standard error z value Odds ratio Lower  95% CI 
Upper  
95% CI p-value 
(Intercept) -0.50 0.10 -4.90 - - - - 
Female sex -0.16 0.05 -3.03 0.85 0.75 0.96 0.002 
Deprivation (per unit increment) -0.09 0.02 -4.69 0.92 0.88 0.95 <0.001 
Heart failure hospitalization 0.74 0.07 10.75 2.09 1.96 2.22 <0.001 
Myocardial infarction 0.08 0.12 0.66 1.08 0.85 1.31 0.512 
Cerebrovascular disease 0.25 0.11 2.27 1.28 1.07 1.49 0.023 
      
Estimates of non-linear smooth functions Estimated degrees of freedom Chi-squared p-value 
s(year) 1.01 4.48 0.035 
s(age_years) 5.64 486.50 <0.001 
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Supplementary table 5: Predicted one-year mortality in women and men from the 








Probability 95% LL 95% UL Probability 95% LL 95% UL 
1990 27.32 24.62 30.21 30.66 27.71 33.78 
1991 27.17 24.54 29.96 30.50 27.64 33.51 
1992 27.01 24.46 29.72 30.33 27.57 33.24 
1993 26.86 24.38 29.48 30.16 27.48 32.98 
1994 26.70 24.29 29.26 29.99 27.39 32.73 
1995 26.55 24.19 29.04 29.83 27.30 32.49 
1996 26.39 24.09 28.83 29.66 27.20 32.26 
1997 26.24 23.98 28.63 29.50 27.09 32.03 
1998 26.09 23.86 28.44 29.33 26.97 31.82 
1999 25.93 23.73 28.26 29.17 26.84 31.61 
2000 25.78 23.60 28.09 29.01 26.71 31.42 
2001 25.63 23.45 27.93 28.85 26.56 31.24 
2002 25.48 23.31 27.78 28.68 26.41 31.07 
2003 25.33 23.15 27.64 28.52 26.25 30.90 
2004 25.18 22.99 27.51 28.36 26.08 30.75 
2005 25.03 22.82 27.39 28.20 25.91 30.61 
2006 24.88 22.64 27.27 28.04 25.72 30.48 
2007 24.74 22.46 27.17 27.88 25.53 30.36 
2008 24.59 22.27 27.07 27.72 25.33 30.24 
2009 24.44 22.08 26.97 27.56 25.13 30.14 
2010 24.30 21.88 26.89 27.40 24.92 30.04 
2011 24.15 21.68 26.81 27.25 24.70 29.95 
2012 24.01 21.47 26.73 27.09 24.49 29.86 
2013 23.86 21.27 26.66 26.93 24.26 29.79 
2014 23.72 21.06 26.60 26.78 24.03 29.71 
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Supplementary table 6: Logistic regression model coefficients and standard errors with 
mortality at 30 days as the primary outcome. 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -2.66 0.31 -8.57 <0.001 
Baseline characteristics     
Age 0.02 0.01 1.31 0.191 
Sex 0.08 0.15 0.51 0.612 
Deprivation (per unit increment) 0.02 0.05 0.36 0.720 
Age:sex interaction <0.001 0.009 0.08 0.936 
Co-morbidities     
Heart failure hospitalization 0.59 0.19 3.05 0.002 
Myocardial infarction 0.33 0.28 1.18 0.238 
Cerebrovascular disease 0.18 0.30 0.60 0.546 
Chronic lung disease 0.13 0.18 0.72 0.470 
Diabetes mellitus -0.21 0.21 -0.98 0.328 
Microbiology     
Enterococcus sp. 0.65 0.35 1.86 0.06 
Polymicrobial/other 0.24 0.36 0.66 0.511 
Staphylococcus aureus 1.40 0.20 7.17 <0.001 
Coagulase negative staphylococci 1.26 0.28 4.45 <0.001 




Supplementary table 7: Logistic regression model coefficients and standard errors with 
mortality at 1 year as the primary outcome. 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -1.18 0.23 -5.04 <0.001 
Baseline characteristics     
Age (per 10 years) 0.04 0.01 3.69 <0.001 
Sex -0.14 0.12 -1.16 0.247 
Deprivation (per unit increment) -0.04 0.04 -1.08 0.282 
Age:sex interaction -0.001 0.007 -0.14 0.889 
Co-morbidities     
Heart failure hospitalization 0.87 0.16 5.38 <0.001 
Myocardial infarction 0.42 0.23 1.82 0.069 
Cerebrovascular disease -0.21 0.25 -0.81 0.418 
Chronic lung disease 0.04 0.14 0.30 0.765 
Diabetes mellitus 0.07 0.16 0.43 0.671 
Microbiology     
Enterococcus sp. 1.23 0.26 4.70 <0.001 
Polymicrobial/other 0.71 0.25 2.89 0.004 
Staphylococcus aureus 1.47 0.17 8.69 <0.001 
Coagulase negative staphylococci 1.03 0.25 4.15 <0.001 
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